Barry Gertz Ph.D Overview
Barry Gertz Ph.D General Information
Biography
Dr. Barry Gertz serves as a Board Member at Cytel. He joined Clarus in October 2014 from Merck (NYSE: MRK) where he was Senior Vice President and Head of Global Clinical Development, overseeing all aspects of Merck's clinical research. He serves as a Managing Director at Blackstone Life Sciences. He brings over 30 years of experience in drug development, from exploratory clinical pharmacology to global Phase III trials. While at Merck, he was instrumental in the development and approval of more than 25 new drugs and vaccines, including the blockbuster products Fosamax and Januvia as well as the initial indication for Keytruda. He has co-authored over a hundred scientific publications appearing in the Journal of Clinical Investigation, the Journal of Clinical Endocrinology and Metabolism, and the New England Journal of Medicine. He currently is a member of the Advisory Boards of Abide Therapeutics, the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania School of Medicine and is a member of the Board of Trustees of the Perelman School of Medicine at the University of Pennsylvania. He received his MD, PhD, and BA degrees from the University of Pennsylvania.
Contact Information
Address
- 314 Main Street
- 15th Floor
- Cambridge, MA 02142
- United States
Barry Gertz Ph.D Board Seats (1)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Cytel | Enterprise Systems (Healthcare) | Privately Held (backing) | Private Equity-Backed | Cambridge, MA |
Barry Gertz Ph.D Network (41)
Board Members (30)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Marvin Zelen | Cytel | Self | Cambridge, MA | |
Per Lofberg | Cytel | Self | Cambridge, MA | |
Cytel | Self | Cambridge, MA | ||
Cytel | Nordic Capital | Cambridge, MA | ||
Cytel | Nordic Capital | Cambridge, MA |
Fund Team Members (11)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Paris Panayiotopoulos | Blackstone | Blackstone Life Sciences V | New York, NY |
Paris Panayiotopoulos | Blackstone Life Sciences | Blackstone Life Sciences V | Cambridge, MA |
Blackstone Life Sciences | Cambridge, MA | ||
Blackstone | New York, NY | ||
Blackstone Life Sciences | Cambridge, MA |
Barry Gertz Ph.D Affiliated Funds (2)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Clarus IV | Blackstone Life Sciences | Other | Closed | 2018 | ||||
Blackstone Life Sciences V | Blackstone | Other | Closed | 2020 |
Barry Gertz Ph.D FAQs
-
Who is Barry Gertz Ph.D?
Dr. Barry Gertz serves as a Board Member at Cytel.
-
How much does Barry Gertz Ph.D typically invest?
Barry Gertz Ph.D's median deal size is
. -
What is Barry Gertz Ph.D’s main position?
Barry Gertz Ph.D’s primary position is Managing Director.
-
How many active board seats does Barry Gertz Ph.D hold?
Barry Gertz Ph.D holds a board seat in Cytel.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »